Figure 2.

Overall survival (OS) of anaplastic thyroid cancer patients according to successful patient-derived xenograft (PDX) establishment or not. Patients for whom PDX models were not successfully established (blue curve; n = 13) had a median OS of 1.16 years (range, 0.05-4.38 years), whereas medial OS for patients with successful PDX models (red curve; n = 6) was 0.64 years (range, 0.05-1.43 years). Age, sex, disease stage, BRAF status–adjusted hazard ratio was 2.276 (95% CI, 0.666-7.784; P = .190)